UBS Maintains Neutral on AbbVie, Raises Price Target to $275

Benzinga Newsdesk www.benzinga.com Positive 71.4%

Neg 0% Neu 0% Pos 71.4%

UBS analyst Michael Yee maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $260 to $275.

Comments

No comments yet. Be the first!